Everything below concerns Preclinical research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
== Role in cancer == IRS-1, as a signalling adapter protein, is able to integrate different signalling cascades, which indicates its possible role in cancer progression. IRS-1 protein is known to be involved in various types of cancer, including colorectal, lung, prostate and breast cancer. IRS-1 integrates signalling from insulin receptor (InsR), insulin-like growth factor-1 receptor (IGF1R) and many other cytokine receptors and is elevated in β-catenin induced cells. Some evidence shows that TCF/LEF-β-catenin complexes directly regulate IRS-1. IRS-1 is required for maintenance of neoplasmic phenotype in adenomatous polyposis coli (APC) - mutated cells, it is also needed for transformation in ectopically expressing oncogenic β-catenin cells. IRS-1 dominant-negative mutant functions as tumor suppressor, whereas ectopic IRS-1 stimulates oncogenic transformation. IRS-1 is upregulated in colorectal cancers (CRC) with elevated levels of β-catenin, c-MYC, InsRβ and IGF1R. IRS-1 promotes CRC metastasis to the liver. Decreased apoptosis of crypt stem cells is associated with colon cancer risk. Reduced expression of IRS-1 in Apc (min/+) mutated mice shows increased irradiation-induced apoptosis in crypt. Deficiency in IRS-1 - partial (+/-) or absolute (-/-) - in Apc (min/+) mice demonstrates reduced amount of tumors comparing to IRS-1 (+/+)/ Apc (min/+) mice. In lung adenocarcinoma cell line A549 overexpression of IRS-1 leads to reduced growth. Tumor infiltrating neutrophils have recently been thought to adjust tumor growth and invasiveness.
=== In insects === Insect PαAMs are responsive to O2 concentrations and depends upon Cu2+. Simpson et al 2015 finds insect PαAMs to respond to hypoxia by regulating the activity of several peptide hormones. They find PαAM to probably be an important part of neuroendocrine responses to hypoxia.
Cloud computing/big data analysis tools Artificial intelligence Machine learning Distributed ledger technologies, including blockchain and smart contracts The Internet of Things, a principle developed by Kevin Ashton that explains how simple mechanical objects can be combined into a network to broaden understanding of that object Digital communications technologies, like mobile phones Digital platforms, such as e-commerce platforms, like bighaat, agribegri, Krisikart India, which provide digital information and deliver pesticides and other agro products to farmers' doorsteps. Agro-advisory apps, such as plantix, offer quick and economical detection of crop diseases, while e-extension websites help farmers to increase their profits. Precision agriculture technologies, including Sensors, including food sensors, soil sensors, and Fuel level sensors Guidance and tracking systems (which provide Vehicle location data and are often enabled by a GPS tracking unit, GNSS, RFID, IoT, or Automatic vehicle location) Variable-rate input technologies Automatic section control Advanced imaging technologies, including satellite and drone imagery, as well as Video telematics (which may use a Dashcam), to look at temperature gradients, fertility gradients, moisture gradients, and anomalies in a field Automated machinery and agricultural robots, whose routes can be optimized using a Journey planner. Such fleets can form a localized Intelligent transportation system on the farm, often managed with a Vehicle tracking system or Fleet telematics system.
FAT10 (or Ubiquitin D) is a tandem UBL protein that is also degraded by the proteasome in a ubiquitin independent manner. Recent biochemical and structural studies show that FAT10 is degraded upon binding of NUB1 that unfolds the first UBL of FAT10 enabling engagement by the 26S proteasome. The NUB1-FAT10 complex also exposes a UBL on NUB1 that binds Rpn1, positioning FAT10 above the central channel of the proteasome. Midnolin was identified as a protein that targeted transcription factors to the proteasome for ubiquitin independent degradation. Recent structural studies show that the UBL of midnolin binds Rpn11, a helix binds Rpn1, and the CATCH domain binds the transcription factor, providing a model for how ubiquitin independent degradation occurs. Pathogens also have learned to take advantage of ubiquitin-independent degradation. For plants, a parasitic Phytoplasma, expresses SAP05, a protein that binds transcription factors and target them for degradation by the 26S proteasome by binding the VWA domain of Rpn10. Interestingly, SAP05 does not bind the insect vector Rpn10. Crystal structures show how SAP05 binds both these TFs and Rpn10 indicating that SAP05 places the TFs near the entry of the AAA motor allowing for ubiquitin independent degradation.
glycol Any of a class of aliphatic dihydric alcohols in which the two hydroxy groups are bonded to two different carbon atoms, which are usually but not necessarily adjacent to each other; e.g. ethylene glycol (HOCH2CH2OH).
Sources: en.wikipedia.org
23 January – The largest interstellar organosulfur molecule (2,5-cyclohexadiene-1-thione) so far is identified in a molecular cloud about 27,000 light-years from Earth near the Galactic Center. 24 January – AES Andes abandons the INNA project to produce hydrogen and ammonia in Chile criticised for its potentially negative impact on astronomical observations at Paranal Observatory and Extremely Large Telescope. 27 January – HD 137010 b, a cool Earth-sized transiting exoplanet candidate 146 light years away, orbiting near the outer edge of its star's habitable zone, is discovered in Kepler K2 data from 2017. 28 January – Researchers at Google DeepMind publish a study on AlphaGenome, a deep learning model that predicts the functional effects of genetic variants across multiple regulatory modalities from long DNA sequences, improving interpretation of non-coding regions of the genome.
=== 2020s === During the COVID-19 pandemic, the company was one of the major developers and processors of COVID-19 testing. In March 2020, Labcorp received emergency use authorization from the FDA for a test for SARS-CoV-2. In April 2020, the company developed the first COVID-19 test in which people were able to collect a sample at home. In July 2020, the company was processing 165,000 COVID-19 tests per day. In December 2021, the company acquired Toxikon, a contract research organization developing non-clinical testing services. In February 2022, the company acquired Personal Genome Diagnostics and its liquid biopsy and tissue-based genomic product, for $450 million in cash plus a possible earn-out of an additional $125 million. Also in February 2022, Labcorp entered into agreements with Ascension, one of the nation’s largest Catholic and nonprofit health systems, to manage Ascension's hospital-based laboratories in ten states and purchase assets of the health system's outreach laboratory business. In June 2023, Labcorp completed the corporate spin-off of Fortrea. In August 2024, Labcorp acquired the assets of bankrupt Invitae for $234 million. In December 2025, Labcorp acquired the ambulatory lab businesses from Community Health Services (CHS) in 13 states for $194 million. In January 2026, it was announced that Labcorp had sold select assets of its early development medical device testing business to NAMSA, a medical device testing, clinical research, and regulatory consulting company.
=== Termination stage === Termination: The TE-domain (thio-esterase domain) hydrolyzes the completed polypeptide chain from the PCP-domain of the previous module, thereby often forming cyclic amides (lactams) or cyclic esters (lactones). Also, the peptide can be released by an R-domain that reduces the thioester bond to terminal aldehyde or alcohol.
=== Related drugs === Although described as SNRIs, duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq) are in fact relatively selective as serotonin reuptake inhibitors (SRIs). They are about at least 10-fold selective for inhibition of serotonin reuptake over norepinephrine reuptake. The selectivity ratios are approximately 1:30 for venlafaxine, 1:10 for duloxetine, and 1:14 for desvenlafaxine. At low doses, these SNRIs act mostly as SSRIs; only at higher doses do they also prominently inhibit norepinephrine reuptake. Milnacipran (Ixel, Savella) and its stereoisomer levomilnacipran (Fetzima) are the only widely marketed SNRIs that inhibit serotonin and norepinephrine to similar degrees, both with ratios close to 1:1. Vilazodone (Viibryd) and vortioxetine (Trintellix) are SRIs that also act as modulators of serotonin receptors and are described as serotonin modulators and stimulators (SMS). Vilazodone is a 5-HT1A receptor partial agonist while vortioxetine is a 5-HT1A receptor agonist and 5-HT3 and 5-HT7 receptor antagonist. Litoxetine (SL 81–0385) and lubazodone (YM-992, YM-35995) are similar drugs that were never marketed. They are SRIs and litoxetine is also a 5-HT3 receptor antagonist while lubazodone is also a 5-HT2A receptor antagonist.
== Chemistry == Sargramostim is a recombinant version of GM-CSF, which is a glycoprotein made of 127 amino acids; sargramostim is mixture of three versions of GM-CSF that have molecular weights of 19,500, 16,800 and 15,500 daltons. It is manufactured in yeast.
Sources: en.wikipedia.org
The prefect of Puno, Benito Laso de la Vega, tried to convince his colleagues in Lampa, Agustín Gamarra from Cuzco and Antonio Gutiérrez de la Fuente from Arequipa, of a project of "microfederalism" or "provincial federation" to separate the south and force the whole country to join the Andean federation of Bolívar. Santa Cruz did everything he could to prevent greater autonomy in the regions and persecute any separatist movement. He removed Laso from his duties and warned the other two. Later, during the Gran Colombian-Peruvian War, Sucre's anti-Peruvian attitudes were denounced, who, to commemorate the triumph of the Gran Columbian army over the Peruvian advance, ordered the construction of a commemorative obelisk on the site where the battle occurred, with an inscription increasing the number of Peruvian soldiers that took part in action and decreasing their own, in the following terms: "The Peruvian army of 8,000 soldiers that invaded the land of their liberators, was defeated by 4,000 braves from Colombia on February 27, 1829." José de la Mar protested the words on the monument, which he considered triumphalist and erroneous. In addition, he complained about the treatment received by the Peruvian dead and prisoners after the battle, with emphasis on the decapitation of the corpse of Pedro Raulet, one of the officers who fell in Tarqui, whose head was nailed to a pike and paraded through the streets of Cuenca.
=== Enzymatic debridement === Chemical enzymes are fast-acting products that slough off necrotic tissue. These enzymes are derived from micro-organisms including Clostridium histolyticum; or from plants, examples include collagenase, varidase, papain, and bromelain. Some of these enzymatic debriders are selective, while some are not. This method works well on wounds (especially burns) with a large amount of necrotic debris or with eschar formation. However, the results are mixed and the effectiveness is variable. Therefore, this type of debridement is used sparingly and is not considered a standard of care for burn treatments.
Livestock farming is one of the top contributors to deforestation, land degradation, water pollution and desertification. Among other reasons, this has led to the new promising technology of meat bioprinting. One alternative to livestock farming is cultured meat, also known as lab-grown meat. Cultured meat is produced by taking a small biopsy from animals, extracting the myosatellite cells and adding growth serum to multiply the cells. The resulting product is then used as a material for bioprinting meat. The post-processing phase, among other steps, includes adding flavour, vitamins and iron to the product. Yet another alternative is printing a meat analogue. Novameat, a Spanish startup has been able to print a plant-based steak and mimic the texture and appearance of real meat. In 2023, Austrian food tech company Revo Foods launched a 3D printed salmon filet alternative based on mycoprotein in Supermarkets of German REWE Group, which became the first 3D printed meat/seafood alternative available in supermarkets worldwide, marking an important milestone towards increased availability of 3D printed food items.
Eliminates competition between male and female Osedax as resources are limited, Sessile lifestyle: attach to and rely on females for food, Decreases difficulty in finding a mate. Interestingly, Osedax priapus lack the frequently observed male dwarfism. Males live freely and compete for space and food with females. Being larger, they produce and carry more sperm. However, sexual size dimorphism is still observed in O. priapus: most males are one-third the volume of females. Annelid sex is typically determined by genetic factors, however models of environmental sex determination have been proposed for Osedax, in which larvae that settle on bones mature into females, while larvae that settle on female Osedax do not fully develop and mature into males. Osedax japonicus in particular has showcased an environmental form of sex determination.
=== Industrial === Industrial production of B12 is achieved through fermentation of selected microorganisms. Streptomyces griseus, a bacterium once thought to be a fungus, was the commercial source of vitamin B12 for many years. The species Pseudomonas denitrificans and Propionibacterium freudenreichii subsp. shermanii are more commonly used today. These are grown under special conditions to enhance yield. Rhone-Poulenc improved yield via genetic engineering P. denitrificans. Propionibacterium, the other commonly used bacteria, produce no exotoxins or endotoxins and are generally recognized as safe (have been granted GRAS status) by the Food and Drug Administration of the United States. The total world production of vitamin B12 in 2008 was 35,000 kg (77,000 lb).
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.